Atomo Diagnostics Ltd
ASX:AT1
Intrinsic Value
Atomo Diagnostics Ltd. engages in manufacturing, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. [ Read More ]
The intrinsic value of one
AT1
stock under the Base Case scenario is
0.02
AUD.
Compared to the current market price of 0.03 AUD,
Atomo Diagnostics Ltd
is
Overvalued by 32%.
AT1's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
AT1 or that its price is influenced by factors unrelated to fundamentals.
Atomo Diagnostics Ltd's market capitalization is 19.2m AUD.
AT1 stock price is 0.03 AUD.
AT1 stock (0.02 AUD) is 32% less than its price (0.03 AUD).
AT1. Open DCF Valuation
AT1 stock (0.02 AUD) is 32% less than its price (0.03 AUD). Open Relative Valuation
AT1 has upside potential of 267% compared to the average analyst price target.
Open Wall St Estimates
AT1's Revenue has dropped by 63% over the past 12 months.
AT1's ROE (Return on Equity) has significantly increased in the last 3 years from -74% to -45%, and is approaching profitability.
AT1's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -45% to -83%, and is approaching profitability.
AT1 has positive Gross Profit for the last twelve months.
AT1 has negative Operating Income for the last twelve months.
AT1 has negative Net Income for the last twelve months.
AT1's ROE (Return on Equity) for the past 12 months is negative and is equal to -45%.
AT1's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -83%.
AT1's Revenue has been falling by 30% per year for the last 3 years.
AT1 has negative Free Cash Flow for the last twelve months.
AT1 has negative three-year average ROE (Return on Equity): -38%. The company is not efficient at transforming stockholders' equity into net income.
AT1 has negative three-year average ROIC (Return on Invested Capital): -58%. The company is not efficient at using invested capital to generate operating income.
AT1's short-term assets (10m AUD) exceed its short-term liabilties (1m AUD).
AT1's long-term assets (15m AUD) exceed its long-term liabilties (1m AUD).
AT1's D/E (Debt to Equity) is very low and is equal to 0.
AT1's Altman Z-Score is very low and is equal to 0.36.
Valuation Backtest
Atomo Diagnostics Ltd
Run backtest to discover the historical profit from buying and selling
AT1
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Atomo Diagnostics Ltd
Balance Sheet Decomposition
Atomo Diagnostics Ltd
| Current Assets | 9.6m |
| Cash & Short-Term Investments | 6.5m |
| Receivables | 1.3m |
| Other Current Assets | 1.8m |
| Non-Current Assets | 5.3m |
| PP&E | 2.2m |
| Intangibles | 3.1m |
| Current Liabilities | 1.1m |
| Accounts Payable | 690.6k |
| Accrued Liabilities | 245.8k |
| Other Current Liabilities | 171.5k |
| Non-Current Liabilities | 119.7k |
| Other Non-Current Liabilities | 119.7k |
Earnings Waterfall
Atomo Diagnostics Ltd
|
Revenue
|
3.1m
AUD
|
|
Cost of Revenue
|
-1.8m
AUD
|
|
Gross Profit
|
1.3m
AUD
|
|
Operating Expenses
|
-8.5m
AUD
|
|
Operating Income
|
-7.2m
AUD
|
|
Other Expenses
|
-147.7k
AUD
|
|
Net Income
|
-7.4m
AUD
|
Free Cash Flow Analysis
Atomo Diagnostics Ltd
What is Free Cash Flow?
AT1 Profitability Score
Profitability Due Diligence
Atomo Diagnostics Ltd's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Atomo Diagnostics Ltd's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
AT1 Solvency Score
Solvency Due Diligence
Atomo Diagnostics Ltd's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Atomo Diagnostics Ltd's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AT1 Price Targets Summary
Atomo Diagnostics Ltd
According to Wall Street analysts, the average 1-year price target for
AT1
is 0.11 AUD
.
Shareholder Return
AT1 Price
Atomo Diagnostics Ltd
| Average Annual Return | -35.57% |
| Standard Deviation of Annual Returns | 40.42% |
| Max Drawdown | -96% |
| Market Capitalization | 19.2m AUD |
| Shares Outstanding | 628 840 171 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Atomo Diagnostics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Atomo Diagnostics Ltd. engages in manufacturing, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-04-16. The firm is engaged in the development and sale of medical devices. Its AtomoRapid is offering rapid diagnostic test (RDT) platform, which provides devices to the global diagnostic market. Its RDT device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. The company also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display. The company is also engaged in sales of Atomo branded COVID-19 rapid antibody and antigen tests in Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one
AT1
stock under the Base Case scenario is
0.02
AUD.
Compared to the current market price of 0.03 AUD,
Atomo Diagnostics Ltd
is
Overvalued by 32%.
You don't have any saved screeners yet
